Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
Christopher R. King,Sean P. Collins,Donald B. Fuller,Pin-Chieh Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +6 more
TLDR
Long-term outcome demonstrates that prostate SBRT is well tolerated and has little lasting impact on health-related quality of life (QOL) outcomes among prostate cancer patients following stereotactic body radiation therapy.Citations
More filters
Journal ArticleDOI
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
TL;DR: PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
TL;DR: Although S BRT was associated with lower treatment costs, there appears to be a greater rate of GU toxicity for patients undergoing SBRT compared with IMRT, and prospective correlation with randomized trials is needed.
Journal ArticleDOI
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
Scott C. Morgan,Karen E. Hoffman,D. Andrew Loblaw,Mark K. Buyyounouski,Caroline Patton,Daniel A. Barocas,Søren M. Bentzen,Michael Chang,Jason A. Efstathiou,Patrick Greany,Per H. Halvorsen,Bridget F. Koontz,Colleen A. Lawton,C. Marc Leyrer,Daniel W. Lin,Michael E. Ray,Howard M. Sandler +16 more
TL;DR: Scott C. Morgan, MD, MSc, FRCPC, a Karen Hoffman,MD, MHSc, MPH,b D. Buyyounouski, MDs, MS,d Caroline Patton, MA,e Daniel Barocas, MD , MPH,f Soren Bentzen, DSc, PhD,g Michael Chang, MD,.
Journal ArticleDOI
A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results
Anna M.E. Bruynzeel,S. Tetar,S.S. Oei,Suresh Senan,C.J.A. Haasbeek,Femke O.B. Spoelstra,Anna H.M. Piet,P. Meijnen,Marjolein A.B. Bakker van der Jagt,Tamara Fraikin,Berend J. Slotman,Reindert J.A. van Moorselaar,Frank J. Lagerwaard +12 more
TL;DR: This prospective study of MRgRT in patients with localized prostate cancer observed a low incidence of early GI and GU toxicity, both in clinician- and patient reported outcome measurements.
References
More filters
Journal ArticleDOI
Interpretation of changes in health-related quality of life the remarkable universality of half a standard deviation
TL;DR: In most circumstances, the threshold of discrimination for changes in health-related quality of life for chronic diseases appears to be approximately half a SD, which research in psychology has shown is approximately 1 part in 7.
Journal ArticleDOI
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda,Rodney L. Dunn,Jeff M. Michalski,Howard M. Sandler,Laurel L. Northouse,Larry Hembroff,Xihong Lin,Thomas K. Greenfield,Mark S. Litwin,Mark S. Litwin,Christopher S. Saigal,Arul Mahadevan,Eric A. Klein,Adam S. Kibel,Louis L. Pisters,Deborah A. Kuban,Irving D. Kaplan,Darien Wood,Jay P. Ciezki,Nikhil L. Shah,John T. Wei +20 more
TL;DR: Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function, and these changes influenced satisfaction with treatment outcomes among patients and their spouses or partners.
Journal ArticleDOI
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
TL;DR: EPIC is a robust prostate cancer HRQOL instrument that complements prior instruments by measuring a broad spectrum of urinary, bowel, sexual, and hormonal symptoms, thereby providing a unique tool for comprehensive assessment ofHRQOL issues important in contemporary prostate cancer management.
Journal ArticleDOI
Prevalence and risk factors for erectile dysfunction in the US.
TL;DR: The high prevalence of erectile dysfunction among men with diabetes and hypertension suggests that screening for erectiles dysfunction in these patients may be warranted and physical activity and other measures for the prevention of cardiovascular disease and diabetes may prevent decrease in erectile function.
Journal ArticleDOI
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
TL;DR: PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.
Related Papers (5)
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda,Rodney L. Dunn,Jeff M. Michalski,Howard M. Sandler,Laurel L. Northouse,Larry Hembroff,Xihong Lin,Thomas K. Greenfield,Mark S. Litwin,Mark S. Litwin,Christopher S. Saigal,Arul Mahadevan,Eric A. Klein,Adam S. Kibel,Louis L. Pisters,Deborah A. Kuban,Irving D. Kaplan,Darien Wood,Jay P. Ciezki,Nikhil L. Shah,John T. Wei +20 more